Marksans Pharma strengthens European presence with €7.5 million QliniQ acquisition - CNBC TV18
Marksans Pharma→Teva Pharmaceuticals Ireland and Teva Pharmaceuticals Canada
Jun 1, 2026
Wellgistics Health, Inc. entered into a note purchase agreement dated April 1, 2026 for a private offering of up to $1,250,000 in aggregate principal amount of promissory notes.
The agreement sets the aggregate purchase price at $1,000,000. The filing identifies Dawson James Securities, Inc. as the placement agent. The note purchase agreement is between Wellgistics Health and the investor named on the signature page, with the offering structured as a sale of the Notes under Exhibit A.
Marksans Pharma→Teva Pharmaceuticals Ireland and Teva Pharmaceuticals Canada
Jun 1, 2026
Marksans Pharma→QliniQ
Jun 1, 2026
Frazier Healthcare Partners→Altruix
May 31, 2026
Signos
May 31, 2026
Sterling Bay→Pacific Center
May 29, 2026